Antigen Express Develops Novel Synthetic Peptide Vaccine for Bird Flu

Strategic Insights -

Dr. Douglas Powell, director of immunobiology at Antigen Express, presented at the international Bird Flu Summit in Washington, DC, in February, showcasing the company's novel synthetic peptide vaccine designed to combat the avian influenza virus. The vaccine's strategy employs small protein fragments from the H5 protein, modified to stimulate the immune system's T helper cells. This approach allows for rapid and cost-effective production, circumventing traditional manufacturing limitations. Antigen Express has pioneered peptide vaccine technology, building on the work of founder Dr. Robert Humphreys, who demonstrated the enhanced effectiveness of antigenic peptides with the addition of the MHC class II associated Ii protein (Ii-Key).

Key Takeaways:

  • Antigen Express is developing a novel synthetic peptide vaccine for the avian influenza virus, designed to stimulate the immune system's T helper cells.
  • The vaccine employs small fragments of the H5 protein, modified for maximal stimulation of T helper cells.
  • The manufacturing approach allows for rapid and cost-effective production of large quantities, addressing the limitations of traditional egg-based and cell culture-based methods.
  • Antigen Express has pioneered the development of antigen-specific peptide vaccines, building on the work of founder Dr. Robert Humphreys.
  • The company's technology has been demonstrated to enhance the effectiveness of antigenic peptides with the addition of the MHC class II associated Ii protein (Ii-Key).
  • Interim results from an ongoing clinical trial of an Ii-Key-modified peptide vaccine for HER-2/neu positive cancers are encouraging.

Statistics:

  • The traditional egg-based method and cell culture-based method for H5N1 vaccine production cannot supply quantities sufficient for vaccinating more than a fraction of the U.S. population due to manufacturing limitations.
  • Antigen Express's novel peptide vaccine design strategy can be manufactured in existing facilities, allowing for rapid production of large quantities.
  • The addition of the Ii-Key protein enhanced the effectiveness of antigenic peptides in various cell culture systems and animal models.
  • The ongoing clinical trial of the Ii-Key-modified peptide vaccine for HER-2/neu positive cancers has yielded interim results that are encouraging.

Sources:

  • Health & Medicine Week editors, "Antigen Express Develops Novel Synthetic Peptide Vaccine for Bird Flu," Health & Medicine Week, February 2006, via NewsRx.com.